For research use only. Not for therapeutic Use.
Trofinetide（Cat No.:I009894）is a synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 (IGF-1), developed to treat neurodevelopmental disorders like Rett syndrome. It works by promoting anti-inflammatory and neuroprotective effects, as well as enhancing synaptic function. Trofinetide addresses the neurological deficits associated with Rett syndrome by reducing inflammation and improving neuronal signaling. Administered orally, it has shown promise in improving core symptoms, such as communication, motor function, and behavior in patients. Trofinetide offers a novel therapeutic approach, enhancing quality of life for individuals with Rett syndrome.
| Catalog Number | I009894 |
| CAS Number | 853400-76-7 |
| Synonyms | NNZ-2566; NNZ 2566; NNZ2566; Trofinetide;((S)-1-glycyl-2-methylpyrrolidine-2-carbonyl)-L-glutamic acid |
| Molecular Formula | C13H21N3O6 |
| Purity | 98% |
| Target | Peptide and Derivatives |
| Solubility | Soluble in DMSO, not in water |
| Appearance | Solid |
| Storage | Dry, dark and at 2 - 8 °C for six months or -20°C for two years. |
| IUPAC Name | (2S)-2-[[(2S)-1-(2-aminoacetyl)-2-methylpyrrolidine-2-carbonyl]amino]pentanedioic acid |
| InChI | InChI=1S/C13H21N3O6/c1-13(5-2-6-16(13)9(17)7-14)12(22)15-8(11(20)21)3-4-10(18)19/h8H,2-7,14H2,1H3,(H,15,22)(H,18,19)(H,20,21)/t8-,13-/m0/s1 |
| InChIKey | BUSXWGRAOZQTEY-SDBXPKJASA-N |
| SMILES | C[C@]1(CCCN1C(=O)CN)C(=O)N[C@@H](CCC(=O)O)C(=O)O |
| Reference | </br> 1:Deacon RM, Glass L, Snape M, Hurley MJ, Altimiras FJ, Biekofsky RR, Cogram P. NNZ-2566, a novel analog of (1-3) IGF-1, as a potential therapeutic agent for fragile X syndrome. Neuromolecular Med. 2015 Mar;17(1):71-82. doi: 10.1007/s12017-015-8341-2. Epub 2015 Jan 23. PubMed PMID: 25613838.</br> 2:Cartagena CM, Phillips KL, Williams GL, Konopko M, Tortella FC, Dave JR, Schmid KE. Mechanism of action for NNZ-2566 anti-inflammatory effects following PBBI involves upregulation of immunomodulator ATF3. Neuromolecular Med. 2013 Sep;15(3):504-14. doi: 10.1007/s12017-013-8236-z. Epub 2013 Jun 14. PubMed PMID: 23765588.</br> 3:Wei HH, Lu XC, Shear DA, Waghray A, Yao C, Tortella FC, Dave JR. NNZ-2566 treatment inhibits neuroinflammation and pro-inflammatory cytokine expression induced by experimental penetrating ballistic-like brain injury in rats. J Neuroinflammation. 2009 Aug 5;6:19. doi: 10.1186/1742-2094-6-19. PubMed PMID: 19656406; PubMed Central PMCID: PMC2731085. |
